Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 2,500 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 2,500 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were purchased at an average price of $12.51 per share, for a total transaction of $31,275.00. Following the acquisition, the chief executive officer now directly owns 5,552,502 shares of the company’s stock, valued at $69,461,800.02. This trade represents a 0.05 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Tuesday, January 7th, Snehal Patel acquired 1,800 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $13.75 per share, for a total transaction of $24,750.00.
• On Thursday, January 2nd, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $11.97 per share, with a total value of $23,940.00.
• On Monday, December 30th, Snehal Patel purchased 3,200 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $11.12 per share, for a total transaction of $35,584.00.

Greenwich LifeSciences Trading Up 3.4 %

Shares of NASDAQ GLSI opened at $12.47 on Thursday. Greenwich LifeSciences, Inc. has a one year low of $8.00 and a one year high of $21.44. The business has a 50-day moving average price of $13.08 and a two-hundred day moving average price of $14.01. The firm has a market capitalization of $163.92 million, a PE ratio of -15.59 and a beta of 1.66.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after buying an additional 5,861 shares in the last quarter. State Street Corp raised its holdings in shares of Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after acquiring an additional 3,005 shares in the last quarter. Garden State Investment Advisory Services LLC acquired a new stake in Greenwich LifeSciences during the third quarter valued at $253,000. Bank of New York Mellon Corp purchased a new position in Greenwich LifeSciences in the second quarter valued at about $264,000. Finally, Barclays PLC increased its position in Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after purchasing an additional 6,538 shares during the last quarter. 4.16% of the stock is owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.